Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060175 | 0.87 | LMNA (0.48) | LMNASMN1; SMN2ESRRBESRRGCACNA1I | |
| SCHEMBL8234505 | 0.85 | LMNA (0.45) | LMNASMN1; SMN2ESRRBESRRGCACNA1I | |
| SCHEMBL3030394 | 0.74 | ESRRB (0.49) | LMNASMN1; SMN2ESRRBESRRGCACNA1I | |
| SCHEMBL3035287 | 0.72 | ESRRB (0.49) | LMNASMN1; SMN2ESRRBESRRGCACNA1I | |
| SCHEMBL3576786 | 0.71 | P2RX7 (0.50) | LMNAPOLBEPHX2NR1H4 | |
| SCHEMBL3273904 | 0.70 | LMNA (0.70) | LMNASMN1; SMN2ESRRBESRRGCA12 | |
| SCHEMBL1063550 | 0.69 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2CA1CA2 | |
| Hydrochloric Acid SCHEMBL4026084 | 0.69 | LMNA (0.68) | LMNASMN1; SMN2ESRRBESRRGCA12 | |
| SCHEMBL3202382 | 0.69 | LMNA (0.53) | LMNASMN1; SMN2 | |
| SCHEMBL1063236 | 0.68 | F2 (0.47) | LMNASMN1; SMN2ESRRBESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | claimed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | claimed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | claimed |
| CN-101466676-A | Pyridyl amide T-type calcium channel antagonists | MERCK & CO INC (US) | 2009-06-24 | — | — | CN | claimed |
| EP-2010493-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | claimed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | LMNA 1410/4885SMN1; SMN2 2344/4885ESRRB 4846/4885 |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | LMNA 1410/4885SMN1; SMN2 2344/4885ESRRB 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.